Butterfly Network Inc
$ 4.44
3.74%
14 Apr - close price
- Market Cap 1,089,829,000 USD
- Current Price $ 4.44
- High / Low $ 4.48 / 4.30
- Stock P/E N/A
- Book Value 0.77
- EPS -0.31
- Next Earning Report 2026-05-01
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.42 %
- 52 Week High 5.03
- 52 Week Low 1.32
About
Butterfly Network, Inc., a digital health company, develops, manufactures, and markets ultrasound imaging solutions in the United States and internationally. The company is headquartered in Guilford, Connecticut.
Analyst Target Price
$5.56
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-10-31 | 2025-07-30 | 2025-04-29 | 2025-02-26 | 2024-11-01 | 2024-08-01 | 2024-05-01 | 2024-02-28 | 2023-11-02 | 2023-08-03 | 2023-05-11 |
| Reported EPS | -0.02 | -0.13 | -0.03 | -0.04 | -0.08 | -0.08 | -0.07 | -0.1 | -0.21 | -0.13 | -0.14 | -0.17 |
| Estimated EPS | -0.05 | -0.04 | -0.06 | -0.07 | -0.08 | -0.09 | -0.1 | -0.12 | -0.13 | -0.15 | -0.16 | -0.21 |
| Surprise | 0.03 | -0.09 | 0.03 | 0.03 | 0 | 0.01 | 0.03 | 0.02 | -0.08 | 0.02 | 0.02 | 0.04 |
| Surprise Percentage | 60% | -225% | 50% | 42.8571% | 0% | 11.1111% | 30% | 16.6667% | -61.5385% | 13.3333% | 12.5% | 19.0476% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-01 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BFLY
2026-03-31 08:10:57
Shares of contract research organizations (CROs) have dropped due to fears that AI advancements could allow drugmakers to conduct clinical trials in-house. However, industry experts and analysts argue that the selloff overestimates AI's ability to replace CROs' core services, such as global patient recruitment and trial execution, suggesting that AI is more likely to enhance efficiency rather than disrupt the sector. While investors are concerned, analysts believe there's no evidence of pharma companies reducing CRO spending due to AI, viewing it as a potential tailwind instead of a threat.
2026-03-30 15:37:00
Butterfly Network has received FDA clearance for its gestational age (GA) tool, making it the first company in the US to have such a tool approved for market. Integrated into its handheld ultrasound system, the AI-based tool can estimate GA in under two minutes, trained on over 21 million images. This clearance will facilitate the expansion of its POCUS with the GA tool in sub-Saharan Africa and the US, addressing critical needs in emergency settings, high-mortality countries, and rural communities.
2026-03-30 08:03:00
Butterfly Network (NYSE: BFLY) has received FDA clearance for its fully automated Gestational Age (GA) Tool, an AI-powered blind-sweep ultrasound solution designed to estimate gestational age in minutes. This tool aims to address critical gaps in maternal care by providing timely and accurate information, particularly in underserved rural areas in the U.S. and low- and middle-income countries. The AI, trained on over 21 million images, offers reliable gestational age estimates with minimal user variability, significantly improving access to essential prenatal imaging and potentially reducing maternal and fetal mortality worldwide.
2026-03-27 18:38:58
Vanguard Group has reported a zero beneficial ownership stake in Butterfly Network Inc. (BFLY) through an amendment to a Schedule 13G/A filing. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately. The filing confirms that The Vanguard Group itself no longer holds shares in Butterfly Network, but does not preclude its affiliates from doing so.
2026-03-17 20:39:32
Butterfly Network founder Jonathan M. Rothberg, Ph.D., has filed an amended Schedule 13D, disclosing an update to his ownership and the establishment of a Rule 10b5-1 trading plan for estate planning. The plan allows for the potential sale of up to 2,799,818 Class A shares and 5,000,000 Class B shares between July 14, 2026, and July 14, 2027, subject to specific price and volume conditions. Rothberg maintains significant ownership, including 1.6% of Class A stock and 100% of Class B stock, primarily through various 4C Holdings entities and family trusts.
2026-03-10 17:52:18
Butterfly Network has appointed David Horsley as Senior Vice President, Innovation for Butterfly Embedded™. This strategic hire is expected to leverage Horsley's extensive experience in ultrasound technology and product development to enhance Butterfly's mission of making ultrasound more accessible and integrated into various healthcare settings. His role will focus on advancing the company's embedded ultrasound solutions.
